7Baggers
Quarterly
Annual
    Unit: USD2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 
      
    		               
      operating activities
    		               
      net income
    		-4,510,000 -57,384,000 -279,544,000 8,470,000 -3,484,000 88,553,000 4,174,000 7,834,000 9,064,000 4,606,000 3,738,000 -14,169,000 4,544,000 -24,353,000 -10,522,000 
      adjustments to reconcile net income to net cash from operating activities:
    		               
      depreciation and amortization
    		5,696,000 4,908,000 10,357,000 6,480,000 6,484,000 8,363,000 8,170,000 8,164,000 8,699,000 7,379,000 7,412,000 7,474,000 6,812,000 6,963,000 6,149,000 
      amortization of debt issuance costs and royalty rights
    		107,000 105,000 102,000 101,000 147,000 176,000          
      recurring fair value measurements of assets and liabilities
    		 -17,870,000 -17,020,000 241,000 9,167,000           
      debt-related expenses
    		 0 0 0 9,918,000           
      provisions for inventory and other assets
    		1,428,000 1,159,000 739,000 318,000 1,072,000           
      stock-based compensation
    		1,207,000 2,642,000 1,865,000 2,205,000 2,446,000 2,388,000 2,400,000 1,734,000 982,000 949,000 867,000 957,000 772,000 3,886,000 1,511,000 
      deferred income taxes
    		 29,009,000 48,577,000 -18,000 -1,367,000           
      changes in assets and liabilities:
    		               
      accounts receivable
    		5,054,000 14,804,000 30,116,000 4,858,000 -1,109,000 -677,000 3,857,000 385,000 -4,561,000 -8,216,000 9,323,000 -6,227,000 5,109,000 -5,144,000 -4,470,000 
      inventories
    		-2,344,000 3,925,000 -2,387,000 -2,909,000 -3,602,000 1,014,000 -2,578,000 -3,007,000 -2,022,000 -2,049,000 1,362,000 2,324,000 2,631,000 501,000 -1,304,000 
      prepaid and other assets
    		1,921,000 -7,938,000 2,480,000 2,465,000 1,824,000 -5,269,000 1,180,000 2,263,000 9,845,000 -2,698,000 -863,000 3,245,000 3,395,000 1,981,000 4,006,000 
      accounts payable and other accrued liabilities
    		-134,000 -7,825,000 -26,429,000 5,196,000 -290,000 -3,015,000 -6,948,000 1,266,000 -1,511,000 -6,294,000 -18,472,000 12,816,000 -16,749,000 -10,122,000 -5,110,000 
      accrued rebates, returns and discounts
    		-267,000 -1,286,000 -4,458,000 -9,456,000 2,887,000 822,000 -3,727,000 -3,257,000 2,926,000 8,832,000 -1,278,000 -5,028,000 -12,978,000 14,199,000 -3,508,000 
      interest payable
    		-650,000 650,000 -650,000 650,000 -1,376,000  -1,032,000 -2,500,000 2,300,000  2,450,000 -2,660,000 2,610,000 -3,461,000 3,075,000 
      net cash from operating activities
    		7,508,000 5,707,000 2,579,000 18,601,000 22,717,000 26,697,000 10,045,000 14,430,000 27,426,000 4,131,000 4,654,000 964,000 -4,226,000 -5,982,000 -14,431,000 
      capex
    		0 -100,000 0 0 0 0 0 0 0 0 0 0 0 0 -1,000 
      free cash flows
    		7,508,000 5,607,000 2,579,000 18,601,000 22,717,000 26,697,000 10,045,000 14,430,000 27,426,000 4,131,000 4,654,000 964,000 -4,226,000 -5,982,000 -14,432,000 
      investing activities
    		               
      purchase of sympazan
    		 -139,000 0 -175,000 -105,000           
      net cash from investing activities
    		 -239,000 4,144,000 -703,000 -105,000 -25,784,000 -371,000 -16,114,000 -404,000     0 -1,000 
      financing activities
    		               
      payments in connection with 2027 convertible notes
    		 0 0             
      payment of direct transaction costs related to convertible debt inducement
    		 0 0 0 -1,119,000           
      payment of contingent consideration
    		 -8,786,000 0 -8,799,000 -6,609,000 0 -4,000,000 -2,000,000 -1,845,000 -2,312,000 0     
      payments related to the vesting and settlement of equity awards
    		-206,000 -128,000 177,000             
      net cash from financing activities
    		-206,000 -8,915,000 -10,000 -16,326,000 -18,950,000 -798,000 2,888,000 -7,441,000 -2,443,000 -7,522,000 -356,000 -7,569,000 44,473,000 -7,969,000 -10,234,000 
      net increase in cash and cash equivalents
    		7,302,000 -3,447,000 6,713,000 1,572,000 3,662,000 115,000 12,562,000 -9,125,000 24,579,000 -21,916,000 4,298,000 -6,605,000 40,247,000   
      cash and cash equivalents at beginning of year
    		73,441,000 0 0 0 64,941,000 0 0 0 36,810,000 0 0 0 20,786,000 0 0 
      cash and cash equivalents at end of period
    		80,743,000  6,713,000 1,572,000 68,603,000  12,562,000 -9,125,000 61,389,000 -21,916,000 4,298,000 -6,605,000 61,033,000 -13,951,000 -24,666,000 
      supplemental disclosure of cash flow information
    		               
      net cash paid for income taxes
    		11,000              469,000 
      cash paid for interest
    		1,300,000 0 1,300,000 0 2,351,000 0 3,004,000   4,908,000 0   5,498,000 887,000 
      loss on impairment of intangible assets
    		 40,808,000              
      gain on extinguishment of debt
    		               
      changes in assets and liabilities, net of acquisition:
    		               
      purchases of property and equipment
    		 -100,000 0           0 -1,000 
      purchase of otrexup
    		     -10,138,000 -371,000 -16,114,000 -404,000       
      net cash acquired in spectrum merger
    		 0              
      proceeds from the sale of investments
    		               
      proceeds from issuance of 2027 convertible notes
    		     4,084,000          
      payment in connection with 2024 senior notes
    		     0          
      payment of debt issuance costs
    		               
      payment of royalty rights
    		     -667,000 0   -458,000 -12,000     
      proceeds from issuance of common stock
    		     0 0   0 0 0 44,861,000   
      other financing activities
    		 458,000              
      cash and cash equivalents at end of year
    		               
      net cash paid (refunded) for income taxes
    		 607,000 1,129,000 2,266,000 29,000    -8,360,000       
      proceeds from sale of investments
    		             0 0 
      proceeds from the issuance of common stock
    		               
      proceeds from exercise of stock options
    		         0 0     
      payment in settlement of convertible debt inducement
    		    -10,500,000           
      payment of taxes related to net share settlement of equity awards
    		    -722,000           
      payments in connection with convertible notes
    		         0      
      shares withheld for payment of employee's withholding tax liability
    		     -165,000 -28,000 -81,000 -598,000 -2,000 -9,000 -19,000 -388,000  27,000 
      net cash received for refund of income taxes
    		               
      supplemental disclosure of non-cash investing activities
    		               
      deferred payments for acquisition of otrexup intangible assets
    		               
      recurring fair value measurement of assets and liabilities
    		      3,900,000 1,300,000 1,645,000 2,011,000 300,000 2,195,000 -593,000 -356,000 1,856,000 
      benefit from inventory and other assets
    		      569,000 228,000 31,000  -226,000 -11,000 151,000  753,000 
      payments in connection with 2021 convertible notes
    		               
      net cash refunded for income taxes
    		      538,000         
      amortization of royalty rights
    		               
      payment in connection with series a-1 and a-2 debt
    		         -4,750,000 0     
      amortization of debt discount, debt issuance costs and royalty rights
    		        28,000 35,000 41,000 48,000 70,000 66,000  
      impairment of goodwill
    		               
      loss on disposal of equipment and early termination of leases
    		               
      income tax provision
    		               
      gain on sale of gralise
    		             0 0 
      loss on sale of nucynta
    		             0 0 
      loss on extinguishment of convertible notes
    		               
      loss on prepayment of senior notes
    		             0 0 
      income taxes
    		               
      cash acquired in zyla merger
    		             0 0 
      proceeds from sale of nucynta
    		             0 0 
      proceeds from sale of gralise
    		             0 0 
      payments in connection with senior notes settlement
    		              0 
      payments on promissory note
    		             0 0 
      payments on revolver
    		             0 0 
      net cash refund of income taxes
    		               
      acquisition of otrexup intangible assets
    		               
      other
    		               
      payments in connection with convertible notes extinguishment
    		              0 
      impairment of goodwill and intangible assets
    		               
      gain on extinguishment of convertible notes
    		             0  
      income taxes receivable
    		               
      purchases of marketable securities
    		               
      maturities of marketable securities
    		               
      sales of marketable securities
    		               
      payments in connection with debt extinguishment
    		               
      repayment of senior notes
    		               
      payment in connection with 13% senior secured notes
    		               
      payment of contingent consideration liability
    		               
      payment of royalty rights obligation
    		               
      payment of employees' tax liability related to common shares withheld
    		               
      convertible notes issuance costs
    		               
      fees for modification of senior notes
    		               
      net decrease in cash and cash equivalents
    		             -13,951,000  
      net cash refund of (paid for) income taxes
    		               
      capital expenditures incurred but not yet paid
    		               
      loss on disposal of equipment
    		               
      deferred income tax benefit
    		               
      income tax receivable
    		               
      income taxes payable
    		               
      accretion of debt discount and debt issuance costs
    		               
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.